Differential toll-like receptor 3 (TLR3) expression and apoptotic response to TLR3 agonist in human neuroblastoma cells

Journal of Biomedical Science

Volumn 18, Issue 1, 2011, Pages

  Chuang, Jiin Haur ^a,b   Chuang, Hui Ching ^a,b   Huang, Chao Cheng ^a   Wu, Chia Ling ^a   Du, Yung Ying ^a   Kung, Mei Lang ^c   Chen, Chih Hao ^d   Chen, San Cher ^c   Tai, Ming Hong ^c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

apoptosis; neuroblastoma; poly(I:C); toll like receptor 3

Indexed keywords

2 AMINOPURINE; CASPASE 3; DOUBLE STRANDED RNA; INTERFERON REGULATORY FACTOR 3; MESSENGER RNA; NEUTRALIZING ANTIBODY; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN KINASE R; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR AGONIST; TLR3 PROTEIN, HUMAN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; FLOW CYTOMETRY; GANGLIONEUROMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; NERVE CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; STROMA CELL; TUMOR DIFFERENTIATION; TUMOR GROWTH; WESTERN BLOTTING; DRUG EFFECT; DRUG POTENTIATION; GENETICS; IMMUNOBLOTTING; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

DSRNA VIRUSES;

2-AMINOPURINE; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; POLY I-C; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3;

EID: 80052030742     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-18-65     Document Type: Article

References (39)

1. Neuroblastoma. Maris JM, Hogarty MD, Bagatell R, Cohn SL, Lancet 2007 369 9579 2106 2120 10.1016/S0140-6736(07)60983-0 17586306 (Pubitemid 46935947)
2. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, Conte M, Casale F, Viscardi E, Bianchi M, D'Angelo P, et al. Eur J Cancer 2009 45 16 2835 2842 10.1016/j.ejca.2009.06.010 19616426
3. Taiwan Pediatric Oncology Group N2002 Follow-Up Report.
4. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM, Science 1984 224 4653 1121 1124 10.1126/science.6719137 6719137 (Pubitemid 14106392)
5. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D, N Engl J Med 1985 313 18 1111 1116 10.1056/ NEJM198510313131802 4047115 (Pubitemid 16216827)
6. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT, Cohn SL, J Clin Oncol 2008 26 6 913 918 10.1200/JCO.2007.13.9493 18281664 (Pubitemid 351398084)
7. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Negroni A, Scarpa S, Romeo A, Ferrari S, Modesti A, Raschella G, Cell Growth Differ 1991 2 10 511 518 1751406
8. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Fredlund E, Ringner M, Maris JM, Pahlman S, Proc Natl Acad Sci USA 2008 105 37 14094 14099 10.1073/pnas. 0804455105 18780787
9. The MYCN oncoprotein as a drug development target. Lu X, Pearson A, Lunec J, Cancer Lett 2003 197 1-2 125 130 10.1016/S0304-3835(03)00096-X 12880971 (Pubitemid 36860001)
10. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. Cohn SL, Look AT, Joshi VV, Holbrook T, Salwen H, Chagnovich D, Chesler L, Rowe ST, Valentine MB, Komuro H, et al. Cancer Res 1995 55 4 721 726 7850780
11. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, Stram DO, Gerbing RB, Lukens JN, J Clin Oncol 2000 18 1 18 26 10623689 (Pubitemid 30036332)
12. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. Bagatell R, Rumcheva P, London WB, Cohn SL, Look AT, Brodeur GM, Frantz C, Joshi V, Thorner P, Rao PV, et al. J Clin Oncol 2005 23 34 8819 8827 10.1200/JCO.2004.00.2931 16314642 (Pubitemid 46211528)
13. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy. Suita S, Tajiri T, Kaneko M, Hirai M, Mugishima H, Sugimoto T, Tsuchida Y, J Pediatr Surg 2007 42 3 489 493 10.1016/j.jpedsurg.2006.10.056 17336185
14. Toll, a muscle cell surface molecule, locally inhibits synaptic initiation of the RP3 motoneuron growth cone in Drosophila. Rose D, Zhu X, Kose H, Hoang B, Cho J, Chiba A, Development 1997 124 8 1561 1571 9108372 (Pubitemid 27223171)
15. Toll-like receptors in brain development and homeostasis. Larsen PH, Holm TH, Owens T, Sci STKE 2007 2007 402 e47. 17785714
16. Toll-like receptor 3 is a potent negative regulator of axonal growth in mammals. Cameron JS, Alexopoulou L, Sloane JA, DiBernardo AB, Ma Y, Kosaras B, Flavell R, Strittmatter SM, Volpe J, Sidman R, et al. J Neurosci 2007 27 47 13033 13041 10.1523/JNEUROSCI.4290-06.2007 18032677 (Pubitemid 350159595)
17. TLR2 mediates neuroinflammation and neuronal damage. Hoffmann O, Braun JS, Becker D, Halle A, Freyer D, Dagand E, Lehnardt S, Weber JR, J Immunol 2007 178 10 6476 6481 17475877 (Pubitemid 46717431)
18. Toll-like receptor 8 functions as a negative regulator of neurite outgrowth and inducer of neuronal apoptosis. Ma Y, Li J, Chiu I, Wang Y, Sloane JA, Lu J, Kosaras B, Sidman RL, Volpe JJ, Vartanian T, J Cell Biol 2006 175 2 209 215 10.1083/jcb.200606016 17060494 (Pubitemid 44631415)
19. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS, Glia 2006 54 6 526 535 10.1002/glia.20401 16906541 (Pubitemid 44449333)
20. TLR3 can directly trigger apoptosis in human cancer cells. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T, J Immunol 2006 176 8 4894 4901 16585585
21. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. Khvalevsky E, Rivkin L, Rachmilewitz J, Galun E, Giladi H, J Cell Biochem 2007 100 5 1301 1312 10.1002/jcb.21119 17243100 (Pubitemid 46480411)
22. Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Morikawa T, Sugiyama A, Kume H, Ota S, Kashima T, Tomita K, Kitamura T, Kodama T, Fukayama M, Aburatani H, Clin Cancer Res 2007 13 19 5703 5709 10.1158/1078-0432.CCR-07-0603 17908959 (Pubitemid 47583894)
23. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P, Clin Cancer Res 2007 13 15 Pt 1 4565 4574 17671143 (Pubitemid 47219727)
24. Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway. Jiang Q, Wei H, Tian Z, BMC Cancer 2008 8 12 10.1186/1471-2407-8- 12 18199340 (Pubitemid 351266921)
25. Development of TLR9 agonists for cancer therapy. Krieg AM, J Clin Invest 2007 117 5 1184 1194 10.1172/JCI31414 17476348 (Pubitemid 46718403)
26. Induction of protein kinase PKR-dependent activation of interferon regulatory factor 3 by vaccinia virus occurs through adapter IPS-1 signaling. Zhang P, Samuel CE, J Biol Chem 2008 283 50 34580 34587 10.1074/jbc.M807029200 18927075
27. Apoptosis in peripheral neuroblastic tumors. Immunohistochemical expression of bcl-2 and p53 is related to DNA fragmentation. Mejia C, Navarro S, Llombart-Bosch A, Histol Histopathol 2007 22 12 1365 1370 17701916 (Pubitemid 47484667)
28. Double-stranded RNA signals antiviral and inflammatory programs and dysfunctional glutamate transport in TLR3-expressing astrocytes. Scumpia PO, Kelly KM, Reeves WH, Stevens BR, Glia 2005 52 2 153 162 10.1002/glia.20234 15920723 (Pubitemid 41652919)
29. Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-mediated differential signaling. Kalali BN, Kollisch G, Mages J, Muller T, Bauer S, Wagner H, Ring J, Lang R, Mempel M, Ollert M, J Immunol 2008 181 4 2694 2704 18684960
30. The RNA-activated protein kinase enhances the induction of interferon-beta and apoptosis mediated by cytoplasmic RNA sensors. McAllister CS, Samuel CE, J Biol Chem 2009 284 3 1644 1651 19028691
31. Innate immune response to double-stranded RNA in biliary epithelial cells is associated with the pathogenesis of biliary atresia. Harada K, Sato Y, Itatsu K, Isse K, Ikeda H, Yasoshima M, Zen Y, Matsui A, Nakanuma Y, Hepatology 2007 46 4 1146 1154 10.1002/hep.21797 17661372 (Pubitemid 350144779)
32. Toll-like receptor 3 associates with c-Src tyrosine kinase on endosomes to initiate antiviral signaling. Johnsen IB, Nguyen TT, Ringdal M, Tryggestad AM, Bakke O, Lien E, Espevik T, Anthonsen MW, EMBO J 2006 25 14 3335 3346 10.1038/sj.emboj.7601222 16858407 (Pubitemid 44141791)
33. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT, Nat Immunol 2004 5 2 190 198 10.1038/ni1028 14716310 (Pubitemid 38208361)
34. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Ivanov S, Dragoi AM, Wang X, Dallacosta C, Louten J, Musco G, Sitia G, Yap GS, Wan Y, Biron CA, et al. Blood 2007 110 6 1970 1981 10.1182/blood-2006- 09-044776 17548579 (Pubitemid 47443911)
35. Calreticulin expression in neuroblastoma - a novel independent prognostic factor. Hsu WM, Hsieh FJ, Jeng YM, Kuo ML, Chen CN, Lai DM, Hsieh LJ, Wang BT, Tsao PN, Lee H, et al. Ann Oncol 2005 16 2 314 321 10.1093/annonc/mdi062 15668290 (Pubitemid 40309316)
36. GRP78 expression correlates with histologic differentiation and favorable prognosis in neuroblastic tumors. Hsu WM, Hsieh FJ, Jeng YM, Kuo ML, Tsao PN, Lee H, Lin MT, Lai HS, Chen CN, Lai DM, et al. Int J Cancer 2005 113 6 920 927 10.1002/ijc.20693 15514946 (Pubitemid 40096871)
37. The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. Brinkmann MM, Spooner E, Hoebe K, Beutler B, Ploegh HL, Kim YM, J Cell Biol 2007 177 2 265 275 10.1083/jcb.200612056 17452530 (Pubitemid 46658638)
38. IFN-alpha sensitizes human umbilical vein endothelial cells to apoptosis induced by double-stranded RNA. Kaiser WJ, Kaufman JL, Offermann MK, J Immunol 2004 172 3 1699 1710 14734752 (Pubitemid 38116818)
39. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Whitmore MM, DeVeer MJ, Edling A, Oates RK, Simons B, Lindner D, Williams BR, Cancer Res 2004 64 16 5850 5860 10.1158/0008-5472.CAN-04-0063 15313929 (Pubitemid 39095586)